SAN DIEGO & SINGAPORE--(BUSINESS WIRE)--ImmunoScape, a biotechnology company focused on next-generation T Cell receptor (TCR)-based immunotherapies, today announced that three abstracts have been accepted for poster presentations at the 2024 American Association for Cancer Research (AACR) Annual Meeting taking place April 5-10, 2024 in San Diego, California.

Presentation details are as follows:

Title: Discovery and development of T cell receptors targeting MAGE family antigens for adoptive T cell therapy against solid tumors 

Presenter: Juliana Velez Lujan, Ph.D., ImmunoScape, Senior Scientist 

Session Title: Adoptive Cell Therapies 1: Tumor Antigen-Specific T-cells and TCR-T 

Date & Time: Sunday, April 7, 2024, 1:30 p.m. – 5:00 p.m. PT 

Location: Poster Section 1 

Poster Number: 13

Title: Deep Immunomics pipeline for discovery and validation of novel cancer-specific T cell receptors 

Presenter: Hannah Fields, ImmunoScape, Scientist 

Session Title: Adoptive Cell Therapies 1: Tumor Antigen Specific T-cells and TCR-T 

Date & Time: Sunday, April 7, 2024, 1:30 p.m. – 5:00 p.m. PT 

Location: Poster Section 1 

Poster Number: 8

Title: A validated bioinformatics tool-set for predicting TCR specificity 

Presenter: Andreas Wilm, ImmunoScape, Director of Computational Biology 

Session Title: Database Resources, Statistical Methods, and Other Tools 

Date & Time: Monday, April 8, 2024, 1:30 p.m. – 5:00 p.m. PT 

Location: Poster Section 36 

Poster Number: 19

Full abstracts will be available on the AACR Online Program Planner. Following the conference, the posters will be made available under the “Publications” page on ImmunoScape's website.

About ImmunoScape

ImmunoScape is a biotechnology company focused on the discovery and development of next-generation TCR cell therapies in the field of oncology. The company’s proprietary Deep Immunomics technology and machine learning platforms enable highly sensitive, large-scale mining and immune profiling of T cells in cancer patient samples to identify novel, therapeutically relevant TCRs across multiple types of solid tumors. ImmunoScape has multiple discovery programs ongoing and will be progressing towards IND-enabling studies and entry into the clinic. For more information, please visit https://immunoscape.com/.

Contacts

Media
Kalyn Schieffer for ImmunoScape

[email protected]